Suppr超能文献

重组人胰岛素样生长因子(IGF)结合蛋白-1可抑制垂体切除大鼠中由IGF-Ⅰ和生长激素刺激的体细胞生长。

Recombinant human insulin-like growth factor (IGF)-binding protein-1 inhibits somatic growth stimulated by IGF-I and growth hormone in hypophysectomized rats.

作者信息

Cox G N, McDermott M J, Merkel E, Stroh C A, Ko S C, Squires C H, Gleason T M, Russell D

机构信息

Synergen, Inc., Boulder, Colorado 80301.

出版信息

Endocrinology. 1994 Nov;135(5):1913-20. doi: 10.1210/endo.135.5.7525258.

Abstract

We have examined the effects of exogenously administered recombinant human insulin-like growth factor-binding protein-1 (rhIGFBP-1) alone and in combination with recombinant human insulin-like growth factor-I (rhIGF-I) or human GH on weight gain and tibial epiphysis enlargement in hypophysectomized rats. rhIGF-I, given twice daily by sc injection, increased both growth parameters in a dose-dependent manner. Coadministration of increasing amounts of rhIGFBP-1 with a constant amount of rhIGF-I (80 micrograms/injection, given twice daily) resulted in a dose-dependent inhibition of the growth-promoting effects of rhIGF-I. A rhIGFBP-1 dose of 9.8 micrograms/injection (an IGFBP-1/IGF-I molar ratio of 0.04:1) caused no significant effect on rhIGF-I-stimulated growth parameters, whereas a rhIGFBP-1 dose of 1200 micrograms/injection (IGFBP-1/IGF-I molar ratio of 5:1) resulted in 78% or greater inhibition of rhIGF-I-stimulated growth (P < 0.05). rhIGFBP-1 doses of 48 and 240 micrograms/injection (IGFBP-1/IGF-I molar ratios of 0.2:1 and 1:1, respectively) had intermediate inhibitory effects. None of the rhIGFBP-1 doses potentiated the growth-promoting effects of rhIGF-I. Rats treated with rhIGFBP-1 alone (twice daily injections of 9.8, 48, 240, or 1200 micrograms) showed no significant differences in growth parameters compared to rats treated with vehicle. Coadministration of rhIGFBP-1 (1200 micrograms/injection, given twice daily) with GH (15 mU/injection, given twice daily) inhibited weight gain and tibial epiphysis enlargement stimulated by GH by at least 50% in each of two experiments (P < 0.05). These studies demonstrate that nonphosphorylated rhIGFBP-1 can inhibit the growth-promoting effects of rhIGF-I and GH in vivo. The results suggest that in addition to its proposed role in glucose homeostasis, IGFBP-1 may play a role in inhibiting somatic growth and other physiological functions stimulated by IGF-I and GH.

摘要

我们研究了外源性给予重组人胰岛素样生长因子结合蛋白-1(rhIGFBP-1)单独以及与重组人胰岛素样生长因子-I(rhIGF-I)或人生长激素(GH)联合使用对垂体切除大鼠体重增加和胫骨骨骺增大的影响。rhIGF-I通过皮下注射每日两次给药,以剂量依赖方式增加了两种生长参数。将越来越多的rhIGFBP-1与恒定剂量的rhIGF-I(80微克/注射,每日两次)共同给药,导致rhIGF-I的促生长作用出现剂量依赖性抑制。rhIGFBP-1剂量为9.8微克/注射(IGFBP-1/IGF-I摩尔比为0.04:1)对rhIGF-I刺激的生长参数无显著影响,而rhIGFBP-1剂量为1200微克/注射(IGFBP-1/IGF-I摩尔比为5:1)导致rhIGF-I刺激的生长受到78%或更大程度的抑制(P<0.05)。rhIGFBP-1剂量为48和240微克/注射(IGFBP-1/IGF-I摩尔比分别为0.2:1和1:1)具有中等抑制作用。没有一种rhIGFBP-1剂量增强rhIGF-I的促生长作用。单独用rhIGFBP-1治疗的大鼠(每日两次注射9.8、48、240或1200微克)与用赋形剂治疗的大鼠相比,生长参数无显著差异。在两项实验中,将rhIGFBP-1(1200微克/注射,每日两次)与GH(15 mU/注射,每日两次)共同给药,抑制了GH刺激的体重增加和胫骨骨骺增大,每次实验至少抑制50%(P<0.05)。这些研究表明,非磷酸化的rhIGFBP-1在体内可抑制rhIGF-I和GH的促生长作用。结果表明,除了其在葡萄糖稳态中所提出的作用外,IGFBP-1可能在抑制由IGF-I和GH刺激的体细胞生长及其他生理功能中发挥作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验